News

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that plays a major role in suppressing the immune system in many cancer patients. The binding of PD-L1 to the

Under the terms of the license agreement, Gilead will license from Carna worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target. In connection with this

Otezla is a prescription medicine secured approval to treat patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. The drug is also

“We’re pleased to bring this product to market for the customers and patients who will benefit from access to this medicine and who have in the past experienced

Oral delivery could broaden the clinical and commercial opportunities for RNAi therapeutics, which are currently administered with intravenous or subcutaneous dose administration. The results were presented at the

The EC has approved Talzenna as monotherapy treatment for adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally

The latest FDA approval for Botox is for patients aged between two and 17 years whose movement at the joints of the upper limb is restricted due to

This program will be the first of its kind in the San Francisco Bay Area, which serves as a hub of both tech and biotech industries and is

Treatment with biologic medicines can, in some patients, trigger the body’s immune system to develop anti-drug antibodies. These anti-drug antibodies can reduce the effectiveness of the biologic therapy.